PD-002 Mucosal Healing with Vedolizumab in Ulcerative Colitis and Crohn's Disease: Outcomes from the VICTORY Consortium.

Kochhar, Gursimran; Parikh, Malav; Chaudrey, Khadija; More

Inflammatory Bowel Diseases . 23():S6, February 2017.

P-040 Assessing Risk Factors Predicting Loss of Response to Vedolizumab in Ulcerative Colitis and Crohn's Disease: Outcomes from the VICTORY Consortium.

Shmidt, Eugenia; Winters, Adam; Katta, Leah; More

Inflammatory Bowel Diseases . 23():S18, February 2017.

P-049 Validated Prediction Model for Clinical Remission with Vedolizumab in Crohn's Disease: Post Hoc Analysis of GEMINI II Clinical Trial.

Dulai, Parambir; Boland, Brigid; Singh, Siddharth; More

Inflammatory Bowel Diseases . 23():S21, February 2017.

P-033 YI Efficacy and Safety of Vedolizumab for Inflammatory Bowel Disease in Clinical Practice.

Chaudrey, Khadija; Lightner, Amy; Singh, Siddharth; More

Inflammatory Bowel Diseases . 22():S19-S20, March 2016.

P-099 Sex-Based Differences in Adverse Events of Crohn's Disease Patients Treated with Certolizumab Pegol: A Pooled Safety Analysis of 15 Studies.

Kane, Sunanda; Loftus, Edward Jr; Choudhary, Cuckoo; More

Inflammatory Bowel Diseases . 22():S40-S41, March 2016.